4 results
To determine the toxicity of Zirconium-89 (Zr89) labelled Cetuximab in patient with stage IV cancer.
With this trial we want to compare both somatostatin analogues, octreotide and lanreotide, in one trial, so we can see whether there is a difference in effect on liver volume in patients with polycystic livers. Furthermore, we want to find theā¦
To compare belzutifan+lenvatinib to cabozantinib with respect to PFS per Response Criteria in Solid Tumors (RECIST) 1.1 as assessedby blinded independent central review (BICR).
1) To compare disease-free survival (DFS) as assessed by investigator for participants treated with belzutifan plus pembrolizumab versus those receiving placebo plus pembrolizumab